Memory stem T cells (T SCM ) have been proposed as key determinants of immunological memory. However, their exact contribution to a mounting immune response as well as the mechanisms and timing of their in vivo generation are poorly understood. We longitudinally tracked T SCM dynamics in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT), thereby providing novel hints on the contribution of this subset to post transplant immune reconstitution in humans. We found that donor-derived T SCM cells are highly enriched early after HSCT. We showed at the antigen-specific and clonal level that T SCM lymphocytes can differentiate directly from naïve precursors infused within the graft and that the extent of T SCM generation might correlate with IL-7 serum levels. In vivo fate mapping through TCR sequencing allowed defining the in vivo differentiation landscapes of human naïve T cells, supporting the notion that progenies of single naïve cells embrace disparate fates in vivo, and highlighting T SCM as relevant novel players in the diversification of immunological memory following allogeneic HSCT.
Introduction
Upon antigen recognition, naive T cells (T N ) undergo extensive functional and phenotypic changes that drive their differentiation into effectors, committed to rapidly clear the pathogen, and memory cells, able to survive long term, to ensure recall responses in case of pathogen recurrence 1 . The memory compartment is multi-faceted and encompasses multiple Tcell subsets with divergent properties 2 . In addition to central memory (T CM ) and effector memory (T EM ) cells 3 , the spectrum of immunological memory has been recently extended with the identification of memory stem T cells (T SCM ) 4, 5 . Human T SCM lymphocytes express CD45RA, CCR7 and CD62L like T N cells, but differently from T N and similarly to other memory subsets, are characterized by CD95 expression. Gene expression profiling, corroborated by in vitro and in vivo experimental results, posits T SCM upstream T CM and T EM in T-cell ontogeny 4, 5 . However, whether T SCM represent a stable subset, reproducibly generated upon T N priming, and which are the relationships of T SCM with the other memory subsets are still controversial issues. Furthermore, how human T SCM cells are formed in vivo, which are the instructive signals guiding their formation and/or expansion, and when they emerge during the immune response has not been elucidated yet.
The contribution of different memory T-cell subsets (though not T SCM ) to the generation of effective primary and secondary immune responses has been elegantly studied at single-cell level in murine models [6] [7] [8] [9] [10] . In humans, however, this pursuit has been limited by ethical and technical constraints. Hematopoietic stem cell transplantation (HSCT) provides a unique setting to longitudinally study the dynamics of discrete T-cell populations upon transfer directly in humans. During allogeneic T-replete HSCT, the recipient receives a myeloablative and lymphodepleting conditioning that abates the host hematopoietic compartment, followed by the For personal use only. on August 31, 2017. by guest www.bloodjournal.org From infusion of a graft containing not only hematopoietic stem cells but also mature T cells from an allogeneic donor 11 . The conditioning regimen induces systemic inflammation, thereby creating a milieu in which infused donor-derived lymphocytes are exposed to a high (allo)antigenic load.
Therefore, close longitudinal sampling of peripheral blood (PB) and bone marrow (BM) of patients after HSCT may allow tracking primary and/or secondary T-cell responses. We have previously shown that IL-7 and IL-15 are necessary to instruct the generation of human T SCM lymphocytes from naïve precursors in vitro and that T SCM cells, which represent not more than 2-3% of circulating T cells in healthy subjects, are enriched early after HSCT, when these homeostatic cytokines are particularly abundant 5 . Building on these observations, we investigated when and how T SCM emerge upon transplant in vivo, in the clinically relevant setting of haploidentical HSCT with post transplant cyclophosphamide (PT-Cy) 12, 13 . Understanding the complex T SCM dynamics upon allogeneic HSCT may ultimately inform on the role of this novel T-cell subset in post transplant immune reconstitution (IR), and possibly provide novel hints on their physiological role.
Methods

Patients, procedures and biological samples. Twenty consecutive adult patients with high-risk
hematologic malignancies treated with myeloablative haploidentical HSCT in our Hematology Unit were studied. Patients received a treosulfan-based myeloablative conditioning followed by an unmanipulated peripheral blood graft (PBSCs) from an HLA-haploidentical related donor.
Postgrafting graft-versus-host-disease (GVHD) prophylaxis consisted of post-transplant cyclophosphamide (PT-Cy, 50 mg/kg/day) on days 3 and 4, followed by mycophenolate mofetil (15 mg/kg 3 times a day) for 30 days, and sirolimus (target level: 8-15 ng/ mL) for 3 months For personal use only. on August 31, 2017. by guest www.bloodjournal.org From (supplemental Figure 1A ). PB and BM samples of donors, patients and healthy subjects were collected after written informed consent approved from the San Raffaele institutional ethical committee.
Multiparametric Flow Cytometry. Mononuclear cells (PBMCs) were isolated from PB and BM by Ficoll-Hypaque gradient separation (Lymphoprep; Fresenius) and immediately used for subsequent analyses. All phenotypic and functional analyses were performed on freshly isolated samples. Eleven-color immunophenotypic analysis was performed using a LSR Fortessa flow cytometer (BD Biosciences). Each acquisition was calibrated using Rainbow Calibration Particles (Spherotech) to correct for day-to-day variation. For intracellular staining, cells were stained with appropriate surface antibodies, washed, and then fixed and permeabilized with FOXP3 Fix/Perm Buffer Set (Biolegend) following manufacturer instructions. Data were processed using FlowJo version 9.7.5 (TreeStar). T-cell subsets were defined according to the expression of CD45RA, CD62L and CD95 as follows: 1) T N : CD45RA + CD62L + CD95 -; 2) T SCM : CD45RA + CD62L + CD95 -; 3) T CM : CD45RA -CD62L + ; 4) T EM : CD45RA -CD62L -; and 5) T EMRA : CD45RA + CD62L -. Supplemental Material provides detailed information on absolute quantifications, antibodies, fluorochromes, FACS-sorting and gating strategy.
Aldefluor assay to determine ALDH activity. Aldefluor kit (Stem Cell Technologies) was used following manufacturer's instructions, to identify cell populations with high ALDH enzymatic activity. Briefly, PBMCs from leukapheresis or from PB were incubated with Aldefluor substrate for 30 min at 37°C, with and without diethylaminobenzaldehyde (DEAB), and then stained for surface markers. Aldefluor was detected in the green fluorescence channel, and samples treated with DEAB were used as controls to set the gates defining the ALDH + region. TCRB CDR3 region sequencing and analysis. TCRβ chain hypervariable complementaritydetermining region 3 (TCRB CDR3) were amplified and sequenced from DNA extracted from T-cell subsets (T N , T SCM , T CM and T EM/EFF ) FACS-purified (purity>95%) from leukapheresis and from PB harvested 30 days post-HSCT from three consecutive patients using the ImmunoSEQ platform at Adaptive Biotechnologies (Seattle, WA, USA) 14 . TCRB CDR3 region was defined as established by the International ImMunoGeneTics collaboration 15 . Sequences that did not match CDR3 sequences were removed from the analysis. Rearranged CDR3 sequences were classified as nonproductive if they included insertions or deletions resulting in frameshifts or premature stop codons, and were excluded from subsequent analyses, according to the ImmunoSEQ were considered for all LP-samples and for the qualitative analyses of day 30 samples (to avoid inclusion of reading errors). No filters were applied to day 30-samples for quantitative analyses to ensure the inclusion of all substantial count reductions, indicative of clone contraction upon infusion. TCRB sequence counts and T-cell subsets were clustered using Spearman correlation 7 and average linkage; heatmaps were drawn using gplots R package. Circos plots were performed as previously described 16 .
Statistical analysis. Statistical analyses were performed with Prism 5 (GraphPad Software). Data are shown as mean ± S.E.M., unless otherwise specified. Data were analyzed with paired t test when comparing the same subset between different time-points or with unpaired t test or standard ANOVA when comparing across two or more different subsets. For all comparisons, two-sided P values were used, and P<0.05 was considered statistically significant. For linear regression analyses, the best-fit values of the slopes were reported along with goodness-of-fit value (r 2 ), P value of the slope (F test) and 95% confidence band. Significance of the slopes was independently verified using R.
Results
Donor-derived T SCM are selectively enriched early after haploidentical HSCT
To understand the dynamics and fate of human naïve and memory T lymphocytes upon HSCT, donor-derived T-cell subsets were longitudinally tracked within the first month upon infusion into twenty consecutive high-risk hematological patients undergoing haploidentical myeloablative T-replete HSCT with PT-Cy. Patient and donor characteristics are summarized in supplemental Table 1 . Of notice, this HSCT platform (supplemental Figure 1A ) allows tracking of CD3 + T cells even in the first two weeks post-HSCT, a possibility precluded in transplants exploiting anti-thymocyte globulins as in vivo T-cell depleting agent (supplemental Figure 1B) . Their frequency at day 8 was significantly higher than that within the infused graft ( Figure 1D ).
CD4 + T-cell subpopulations displayed superimposable dynamics (supplemental Figure 3 ). In line with T SCM phenotypic characterization previously reported 4,5 , CD8 + and CD4 + T SCM at day 8 post HSCT homogeneously expressed CCR7, CXCR4, CD27 and CD28 (supplemental Figure 4 ).
Notably, serum concentration of IL-7 at day 1 appeared to correlate with the number of circulating CD8 + and CD4 + T SCM lymphocytes measured at day 8 ( Figure 1E 
PT-Cy administration eliminates proliferating T cells but does not prevent T SCM accumulation
To discern whether the high frequency of T SCM observed at day 8 was due to expansion of T SCM infused within the graft or to their direct in vivo generation, we analyzed T-cell subset Figure 2B , grey line, right Y axis), and T SCM cells increased in percentages and counts ( Figure   1 ). These results could be explained either by a selective resistance of cycling T SCM to Cy or by de novo generation of T SCM . We thus explored whether T SCM cells were resistant to PT-Cy. We failed to record ALDH activity in three patients selected according to sample availability, the major mechanism of Cy inactivation 18, 19 , in total CD3 + T cells neither within the graft nor upon Figure 8 ). Overall, these data suggest that CD31 + CD4 + T SCM cells observed at day 8 post-HSCT preferentially derive from CD31 + CD4 + T N infused within the graft.
Conversion of CD8 + T N into T SCM can be traced at the antigen-specific level
To trace the differentiation of antigen-specific 21 CD8 + T N into T SCM , we exploited HLA-A*0201 and -A*0101 dextramer complexes loaded with known immunogenic peptides from WT1 22 or PRAME 23 in PB or BM of leukemic patients. Tumor-specific T cells are usually rare in healthy subjects and, when detectable, invariantly display a naïve phenotype (4) . Indeed, in UPN#4 rare HLA-A*0101 restricted WT1-specific T cells retrieved in the donor LP displayed a T N phenotype. By day 30 after HSCT WT1-specific T cells displayed memory features, and were traceable both in PB and at disease site (BM) with T SCM being detectable in the latter ( Figure   4A ). The same result was obtained in UPN#13, mismatched with the donor for HLA-A*0201.
We traced tumor-specific T cells in 3 additional patients receiving a transplant matched for the restriction element analyzed. Of notice, tumor-specific T cells detected in LP displayed a T N phenotype, while after infusion, anti-tumor T cells acquired a memory phenotype in all patients, and comprised T SCM lymphocytes, although their relative contribution varied across different anatomical sites and different patients ( Figure 4B ). In our series, only one CMV seropositive HLA-B*0702 + patient was transplanted from a CMV seronegative donor, allowing to potentially trace a viral-specific primary immune response. Accordingly, pp65-specific T cells in LP For personal use only. on August 31, 2017. by guest www.bloodjournal.org From displayed a naïve phenotype. We observed the appearance of pp65-specific CD8 + T SCM , in concomitance with viral reactivation (supplemental Figure 9 ). Overall, these observations support direct conversion of human CD8 + T N into T SCM cells in vivo. repertoires at day 30 post-HSCT, while only less than 10% were found in the T SCM repertoire.
Sequences harbored by LP-T EM/EFF were found mainly within day 30 T EM/EFF , although conversion into T CM was also observed (27%). Again, less than 10% of TCRB sequences identified in LP-T EM/EFF were retrieved in the T SCM compartment at day 30 ( Figure 5A ). These data are consistent with a preferential progressive framework of differentiation, following the Figure 13 ). By focusing on those LP-T N -derived sequences that were shared among two or more memory subsets at day 30 post-HSCT, we found that approximately 25% of TCRB sequences were shared among day 30 T SCM , T CM and T EM/EFF , although all other possible combinations could be retrieved ( Figure 5D-E) . The frequency of memory T cell clones originating from individual LP-T N cells was highly variable, and proportional to the level of memory subset diversification retrieved at day 30 post-HSCT ( Figure 5F ), suggesting that singlecell progenies differentiating into multiple subsets were those characterized by the highest clonal burst. Although the relative contribution of single versus multiple fates of T N cells could not be determined, our in vivo fate mapping suggests that in the HSCT context progenies of single T N cells might embrace disparate fates, with phenotypic and functional heterogeneity achieved at population level. Thus, we propose a revision of the linear differentiation model to take into account the discordance in fate of individual T N cells and the intrinsic plasticity of the memory compartment, leading to a branched differentiation model ( Figure 5G ).
Discussion
While stem cell engraftment and hematological reconstitution are carefully monitored during the first month after HSCT, the shape of T-cell dynamics within this timeframe has remained largely unknown so far. Here, we exploited the PT-Cy platform that differently from other HSCT protocols, mainly relying on the infusion of anti-thymocyte globulins, allows a thorough analysis of circulating cells in this delicate early post-transplant phase to explore the contribution of T SCM cells to post-transplant IR. Indeed, we observed that donor-derived T SCM lymphocytes are highly enriched early after HSCT and we showed, at the polyclonal, antigenspecific and clonal level, that T SCM lymphocytes arising soon after HSCT preferentially derive Notably, we showed that IL-7 serum levels measured one day after graft infusion seems to correlate with circulating T SCM counts at day 8, thereby suggesting that IL-7 might be important for T SCM generation not only in vitro 5 but also in vivo. The cytokine milieu in which T cells are activated may differently promote effector versus memory differentiation 31,32 . We could speculate that the increase in circulating IL-7 levels characteristic of the early phase post-HSCT, and associated to the lymphopenic environment, may have favored T SCM generation in this specific context, as also suggested by murine studies 33 . Thus, it remains to be evaluated whether Approximately 30% of virus-specific memory cells in yellow fever vaccinated subjects have been reported to express CD45RA and CCR7 and to persist for years 34, 35 . Similarly, another study identified CD45RA + CCR7 + HIV-specific CD8 + memory T cells functioning as precursors for the other subsets of memory lymphocytes 36 . Notably, in EBV carriers, 10% of EBV-specific memory CD4 + T cells co-express CD45RA and CCR7 37 . Although formal proof that such cells represented T SCM lymphocytes was missing in these reports, these findings strongly support the hypothesis that T SCM lymphocytes are reproducibly generated after immunization in humans.
Differences in the insulting pathogens and tissue environments might impinge on the relative abundance of T SCM generated. Here, we show that T SCM cells have the potential to emerge early after T N priming, without necessarily passing through an effector stage. The mechanisms of T-cell memory formation have been actively debated and several models proposed to explain the divergent developmental fates of T-cell progenies. By exploiting the TCR harbored by single T cells infused within the leukapheresis product as surrogate clonal markers, we attempted to evaluate the in vivo differentiation landscapes of single T-cell progenies after transplant in three consecutive patients. Obviously, in the absence of access to secondary lymphoid organs, peripheral or mucosal tissues, constraints typical of studies involving human subjects, we relied on PB as barometer of the entire organism, and tissueresident progenies of infused lymphocytes could not be included in the present model. With this caveat in mind, we found that upon transfer, discrete T-cell subsets behaved preferentially within a progressive framework of differentiation: infused T N and T SCM were able to reconstitute the entire spectrum of T-cell memory. Interestingly, up to 30% of originally T EM cells could revert to a T CM phenotype, as reported in non-human primates 38 . A limited fraction of T CM and T EM reconverted to T SCM , indicating that the T-cell memory compartment is endowed with a certain degree of plasticity in vivo. Our experimental system was characterized by the use of PT-Cy, which we showed to selectively kill the majority of memory T cells proliferating early after transplant. As a result, TCRB sequences originally harbored by LP-T SCM , -T CM and -T EM were found decreased in counts 30 days after transplant. Differently, T N cells were capable of robustly proliferating and differentiating into memory cells. Progenies of individual T N were plastic and had the ability to generate heterogeneous effector and memory populations, comprising T SCM .
Notably, the experimental evidence that a third of LP-T N clonotypes traced 30 days after HSCT, were found within the T SCM compartment argues against the hypothesis that T SCM may represent a metastable state within a continuum of phenotypes, but rather reinforce the notion that they represent a stable and relevant memory subset. In our study, only a small proportion of T N -progenies were traceable in multiple subsets at day 30, while the majority of T N clones identified in LP were retrieved in a single memory subclass in vivo. Although the relative contribution of single versus multiple cell fates could not be precisely estimated, our data suggest that the rules of memory T-cell differentiation in humans are at least in part based on population averaging of disparate single-cell behaviors, and are reminiscent of the T-cell dynamics recently described in murine models 6, 7, 10 .
Altogether, these results highlight T SCM lineage as a previously not appreciated important player in the diversification of T N cells, and will likely inform strategies aimed at preventing and treating infections 39 , autoimmune diseases 40 and cancer 41 . cells were stained and no less than 10 5 events on the CD3 + gate were recorded; n.a.: sample not available; n.e.: population not evaluable. 
